Back
  1. Home
  2. Profile of Nathalie SARLET (ULiège)
Profil

SARLET Nathalie

Autres Services Médicaux > Service de médecine de l'appareil locomoteur

See author's contact details
Main Referenced Co-authors
Reginster, Jean-Yves  (29)
Deroisy, Rita  (15)
Lecart, Marie-Paule  (9)
Albert, Adelin  (8)
Franchimont, P (7)
Main Referenced Keywords
Calcitonin/therapeutic use (2); Female (2); Humans (2); osteoporosis (2); treatment (2);
Main Referenced Disciplines
General & internal medicine (15)
Rheumatology (11)
Endocrinology, metabolism & nutrition (2)
Anesthesia & intensive care (1)
Pharmacy, pharmacology & toxicology (1)

Publications (total 30)

The most downloaded
224 downloads
Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Sarlet, N., Distèche, S., & Bruyère, O. (2014). Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014? Revue Médicale de Liège, 69 (7-8), 441-53. https://hdl.handle.net/2268/172521

The most cited

163 citations (Scopus®)

Reginster, J.-Y., Lecart, M. P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., & Franchimont, P. (1989). Prevention of Postmenopausal Bone Loss by Tiludronate. The Lancet, 2 (8678-8679, Dec 23-30), 1469-71. doi:10.1016/S0140-6736(89)92927-9 https://hdl.handle.net/2268/125038

ROUSSEAU, A.-F., DEROISY, R., LECART, M.-P., MASSENET, V., SARLET, N., Misset, B., CAVALIER, E., & KAUX, J.-F. (2022). Bone health in survivors of a prolonged ICU stay. Aging Clinical and Experimental Research, 34 (S1), 332.
Peer Reviewed verified by ORBi

Reginster, J.-Y., NEUPREZ, A., LECART, M.-P., Sarlet, N., Distèche, S., & Bruyère, O. (2014). Traitement de l'osteoporose post-menopausique: quoi de neuf en 2014? Revue Médicale de Liège, 69 (7-8), 441-53.
Peer reviewed

Reginster, J.-Y., NEUPREZ, A., Beaudart, C., LECART, M.-P., Sarlet, N., Bernard, D., Distèche, S., & Bruyère, O. (2014). Antiresorptive Drugs Beyond Bisphosphonates and Selective Oestrogen Receptor Modulators for the Management of Postmenopausal Osteoporosis. Drugs and Aging, 31, 413-424. doi:10.1007/s40266-014-0179-z
Peer Reviewed verified by ORBi

REGINSTER, J.-Y., Neuprez, A., LECART, M.-P., SARLET, N., & Bruyère, O. (October 2012). Role of glucosamine in the treatment for osteoarthritis. Rheumatology International, 32 (10), 2959-67. doi:10.1007/s00296-012-2416-2
Peer Reviewed verified by ORBi

Reginster, J.-Y., & Sarlet, N. (2006). The Treatment of Severe Postmenopausal Osteoporosis : A Review of Current and Emerging Therapeutic Options. Treatments in Endocrinology, 5 (1), 15-23. doi:10.2165/00024677-200605010-00003
Peer Reviewed verified by ORBi

Manette, C., Collette, J., Sarlet, N., Tancredi, A., Zegels, B., & Reginster, J.-Y. (2006). Comprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate. Current Medicinal Chemistry, 13 (13), 1585-1590. doi:10.2174/092986706777442057
Peer Reviewed verified by ORBi

Jupsin, I., Collette, J., Henrotin, Y., Bruyère, O., Sarlet, N., & Reginster, J.-Y. (April 2005). Strontium Ranelate (Fujisawa/Servier). Current Opinion in Investigational Drugs, 6 (4), 435-44.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Sarlet, N., LEJEUNE, E., & Leonori, L. (March 2005). Strontium Ranelate: A New Treatment for Postmenopausal Osteoporosis with a Dual Mode of Action. Current Osteoporosis Reports, 3 (1), 30-4. doi:10.1007/s11914-005-0025-7
Peer Reviewed verified by ORBi

Reginster, J.-Y., Sarlet, N., & Lecart, M.-P. (January 2005). Fractures in osteoporosis: the challenge for the new millennium. Osteoporosis International, 16 (Suppl. 1), 1-S3. doi:10.1007/s00198-004-1752-9
Peer Reviewed verified by ORBi

Reginster, J.-Y., LECART, M.-P., & SARLET, N. (2004). Traitement structurel de l'arthrose : le point en 2004. Ortho-Rhumato, 2 (3), 52-54.
Peer reviewed

Reginster, J.-Y., Lecart, M.-P., Sarlet, N., & Halkin, V. (2003). Prevention de la fracture de la hanche chez le sujet age: ou en sommes-nous en 2003? Revue Médicale de Liège, 58 (4), 183-90.
Peer reviewed

Reginster, J.-Y., Zegels, B., Lejeune, E., Micheletti, M. C., Kvsaz, A., Seidel, L., & Sarlet, N. (February 2002). Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion. Calcified Tissue International, 70 (2), 78-82. doi:10.1007/s00223-001-0034-1
Peer Reviewed verified by ORBi

Reginster, J.-Y., de Froidmont, C., Lecart, M. P., Sarlet, N., & Defraigne, J.-O. (October 1999). Alphacalcidol in Prevention of Glucocorticoid-Induced Osteoporosis. Calcified Tissue International, 65 (4), 328-31. doi:10.1007/s002239900706
Peer Reviewed verified by ORBi

Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Denis, D., SARLET, N., Reginster-Haneuse, G., Albert, A., & Boelen, C. (1996). Prévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard. Santé Publique: Revue Multidisciplinaire pour la Recherche et l'Action, 2, 139-150.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Deroisy, R., Lecart, M. P., Sarlet, N., Zegels, B., Jupsin, I., de Longueville, M., & Franchimont, P. (May 1995). A Double-Blind, Placebo-Controlled, Dose-Finding Trial of Intermittent Nasal Salmon Calcitonin for Prevention of Postmenopausal Lumbar Spine Bone Loss. American Journal of Medicine, 98 (5), 452-8. doi:10.1016/S0002-9343(99)80344-1
Peer Reviewed verified by ORBi

Reginster, J.-Y., Denis, D., Deroisy, R., Lecart, M. P., De Longueville, M., Zegels, B., Sarlet, N., Noirfalisse, P., & Franchimont, P. (January 1994). Long-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin. Journal of Bone and Mineral Research, 9 (1), 69-73. doi:10.1002/jbmr.5650090110
Peer Reviewed verified by ORBi

Reginster, J.-Y., DEROISY, R., LECART, M.-P., Zegels, B., Sarlet, N., de Longueville, M., Albert, A., & Franchimont, P. (1993). Nasal salmon calcitonin for prevention of early postmenopausal bone loss: a dose-ranging placebo controlled study. Journal of Bone and Mineral Research, 8 (S1), 340.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Sarlet, N., Deroisy, R., Albert, A., Gaspard, U., & Franchimont, P. (November 1992). Minimal Levels of Serum Estradiol Prevent Postmenopausal Bone Loss. Calcified Tissue International, 51, 340-3. doi:10.1007/BF00316876
Peer Reviewed verified by ORBi

Reginster, J.-Y., Sarlet, N., Albert, A., DEROISY, R., & Franchimont, P. (1992). Estrogen replacement therapy and inhibition of bone resorption. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528.
Peer Reviewed verified by ORBi

Reginster, J.-Y., DEROISY, R., Sarlet, N., & Franchimont, P. (1992). Relation between calcium intake during different periods of life and bone mineral content at the menopause. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527.
Peer Reviewed verified by ORBi

Reginster, J.-Y., JEUGMANS, A.-M., Franssen, M., Sarlet, N., McIntyre, H. D., & Franchimont, P. (January 1992). The Effect of Nasal hCT on Bone Turnover in Paget's Disease of Bone--Implications for the Treatment of Other Metabolic Bone Diseases. British Journal of Rheumatology, 31 (1), 35-9. doi:10.1093/rheumatology/31.1.35
Peer Reviewed verified by ORBi

Reginster, J.-Y., DEROISY, R., Albert, A., Sarlet, N., & Franchimont, P. (1992). Long-term precision of quantitative digital radiology. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 527.
Peer Reviewed verified by ORBi

Reginster, J.-Y., JEUGMANS, A.-M., Wouters, M., Sarlet, N., Mc Intyre, H., & Franchimont, P. (1992). The effect of nasal hCT on bone turnover in Paget's disease of bone. Implications for the treatment of other metabolic bone diseases. Revue du Rhumatisme et des Maladies Osteo-Articulaires, 59, 528.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Denis, D., Deroisy, R., Albert, A., Sarlet, N., Collette, J., & Franchimont, P. (June 1990). Dual Photon Absorptiometry of Lumbar Spine in West European (Belgian) Postmenopausal Females: Normal Range and Fracture Threshold. Clinical Rheumatology, 9 (2), 220-4. doi:10.1007/BF02031972
Peer Reviewed verified by ORBi

Reginster, J.-Y., DEROISY, R., Lecart, M., SARLET, N., Fontaine, M., Albert, A., & Franchimont, P. (1990). Calcitonin and Postmenopausal Bone Loss. Experimental Gerontology, 25, 349-56. doi:10.1016/0531-5565(90)90072-A
Peer Reviewed verified by ORBi

Reginster, J.-Y., Lecart, M., DEROISY, R., SARLET, N., Ethgen, D., & Franchimont, P. (1990). Treatment of Paget's disease of bone with high doses of oral tiludronate given during a five-day course therapy. Journal of Bone and Mineral Research, 5 (S2), 170.
Peer Reviewed verified by ORBi

Reginster, J.-Y., Lecart, M., DEROISY, R., SARLET, N., Denis, D., Albert, A., COLLETTE, J., & Franchimont, P. (1990). Prevention of postmenopausal bone loss by tiludronate. Menopause Digest, 4, 28.
Peer reviewed

Reginster, J.-Y., & SARLET, N. (1989). Prévention et traitement de l'ostéoporose postménopausique. Problèmes Pratiques de Rhumatologie, 19, 1-4.
Peer reviewed

Reginster, J.-Y., Lecart, M. P., Deroisy, R., Sarlet, N., Denis, D., Ethgen, D., Collette, J., & Franchimont, P. (1989). Prevention of Postmenopausal Bone Loss by Tiludronate. The Lancet, 2 (8678-8679, Dec 23-30), 1469-71. doi:10.1016/S0140-6736(89)92927-9
Peer Reviewed verified by ORBi

Reginster, J.-Y., Deroisy, R., Denis, D., Lecart, M. P., Sarlet, N., & Franchimont, P. (September 1988). Is There Any Place for Salmon Calcitonin in Prevention of Postmenopausal Bone Loss? Gynecological Endocrinology, 2 (3), 195-204. doi:10.3109/09513599809029344
Peer Reviewed verified by ORBi

Contact ORBi